https://prostatecancernewstoday.com/2017/10/11/at-prostate-cancer-foundation-retreat-bioxcel-presents-data-on-potential-therapy-bxcl701/ BioXcel Therapeutics’ immuno-oncology candidate BXCL701 was shown to enhance the anti-tumor effects of immune checkpoint inhibitors in prostate models, according to an Oct. 5 poster session at the 24th Annual Prostate Cancer Foundation Scientific Retreat in Washington, D.C. The company reported recent findings from multiple studies showing that BXCL701Continue Reading